Prognostic value of P53 nuclear
overexpression in bladder cancer
Reddy P. V.1
1Dr P. Vedamurthy Reddy, Associate Professor, Dept of Urology &
Renal Transplantation, Narayana Medical College Hospital,
Nellore, Andhra Pradesh, India - 524003
Address for
Correspondence: Dr P. Vedamurthy Reddy, E Mail:
pglreddy@yahoo.co.in
Abstract
Introduction:
Urinary bladder cancer is one of the common genitourinary malignancy
presenting to the urology department. Prognosis of these patients will
depend upon the number of clinicopathological factors. Overexpression
of p53 is associated with aggressive behaviour of bladder cancer. The
purpose of the present study is to assess the role of p53 tumour
suppressor gene as an independent prognostic marker. Materials & Methods:
Thirty-three (33) consecutive cases of urinary bladder cancer attending
Department of Urology between August 2006 to December 2008 were
studied. In this study P53 protein, nuclear over expression was
assessed in Formalin-fixed, paraffin-embedded tissue sections by the
immunohistochemical method using monoclonal antibody. This p53 nuclear
over expression was correlated with tumour grade and stage. Over all
survival rate was assessed in p53 positive and negative patients. Results: Two
patients with T1G1 tumours developed recurrence with initial TURBT and
intravesical BCG instillation after 6 months and responded to Re TURBT
and intravesical BCG instillation therapy. One patient of T1G3
developed recurrence after 1 year with initial TURBT and intravesical
BCG instillation and responded to Re TURBT and intravesical BCG
instillation therapy. One patient of T1G3 progressed to muscle invasive
disease after 1 year and underwent Radical cystoprostatectomy with
ileal conduit received adjuvant chemotherapy and radiotherapy. Two
patients developed post-operative urinary leak and underwent bilateral
cutaneous ureterostomy. Nine patients died in followup period. Conclusion: There
was a strong positive correlation between the expression of mutant p53
and tumour grade, with none of the low-grade tumours were positive for
mutant p53, in contrast to 60% of high-grade tumours. In this study,
there was no significant difference in the mortality between p53
positive and negative patients.
Key Words:
Bladder cancer; p53 nuclear overexpression; Tumor grade,
Immunohistochemistry
Manuscript received:
4th June 2017, Reviewed:
15th June 2017
Author Corrected:
24th June 2017, Accepted
for Publication: 30th June 2017
Introduction
Bladder cancer is one of the commonest malignancies which can occur at
any age and involve both sexes, though predominantly affecting
middle-aged and elderly males. In men, it is the fourth most common
cancer after prostate, lung and colorectal cancers, accounting for 6.6%
of all cancer cases [1]. In women, it is the ninth most common cancer,
accounting for 2.4% of all cancers [1]. Bladder cancer accounts for
3.0% of all cancer deaths in men and 1.5% in women. Males have higher 5
year survival rates than women. In adolescents and in adults younger
than 30-40 years, bladder cancers tend to express well-differentiated
histologies and behave in a more indolent fashion [2]. Regional and
national differences reflect the combined effects of environmental and
hereditary factors. It also reflects national differences in case
reporting [3]. The important molecular mechanism in the process of
carcinogenesis is the inactivation of genes coding for proteins that
regulate cell growth, DNA repair or apoptosis. Deletions or
inactivation of these so-called cancer suppressor genes could encourage
unregulated growth or failure to direct damaged DNA cells to programmed
cell death, ultimately resulting in uncontrolled proliferation of
genetically altered clones. Several suppressor gene loci have been
closely associated with bladder cancer. These include p53 on chromosome
17p, retinoblastoma (Rb) gene on chromosome 13 q, and genes on
chromosome 9.
P53: The p53 gene is the most frequently altered gene in human cancers
[4,5]. The normal protein, wild-type p53, has a variety of functions
including 1) acting as a transcription factor that suppresses cell
proliferation, 2) directing DNA damaged cells toward apoptosis before
DNA replication (S-phase of cell cycle) occurs, 3) contributing to the
repair of damaged DNA by inducing the production of deoxyribonucleotide
triphosphates in the nucleus and other mechanisms [4,5,6,7,8].
P53 mutations have been associated with genomic instability and hence
progressive development of further mutations. Bladder cancers with p53
abnormalities appear to have more aggressive behaviours. For tumours to
exceed 1 or 2 mm in diameter, new blood vessels must feed them.
Wild-type p53 induces the expression of a potent inhibitor of
angiogenesis, thrombospondin-1 (TSP-1), a normal constituent of the
extracellular matrix, where as mutant (or absent) p53 does not. A
correlation of abnormal p53 immunostaining with down-regulation of
TSP-1 and neoangiogenesis has been reported in bladder cancer [9].
MDM-2, whose expression itself is induced by p53, binds to
p53’s aminoterminal, targeting it for ubiquitization and
proteosomal degradation [10]. Failure of this process stabilises p53.
Indeed, wild-type p53 normally lasts only very briefly in the cell
nucleus, where as mutated forms often accumulate for longer times and
hence are more easily detected by immunohistochemistry (IHC) [11]. The
wild-type p53 protein functions as a tetramer, the altered product of a
mutant allele stabilise but inactivates the tetrameric protein and
resulting in tumorigenesis.
Urinary bladder cancer is one of the common genitourinary malignancies
presenting to the urology department. Prognosis of these patients will
depend upon the number of clinicopathological factors. Overexpression
of p53 is associated with aggressive behaviour of bladder cancer. The
purpose of the present study is to assess the role of p53 tumour
suppressor gene as an independent prognostic marker.
Materials
& Methods
Study design-
Thirty-three (33) consecutive cases of urinary bladder cancer attending
Department of Urology between August 2006 to December 2008 were
studied. A detailed history was taken and clinical examination was done
for all patients which were included in the study. Urine was sent for
routine microscopy, culture sensitivity and urine cytology. Routine
blood parameters like hemogram, serum urea, serum creatinine, blood
sugar and coagulation profile were done. Ultrasound abdomen, Contrast
enhanced computer tomography (CECT) abdomen and plain CT abdomen in
patients with renal failure were done for diagnosis of bladder tumours
and for clinical staging.
Patients were managed according to the stage and general condition with
bladder tumour biopsy, transurethral resection of bladder tumour
(TURBT) and Radical cystectomy with urinary diversion followed by
adjuvant intravesical BCG instillation, chemotherapy and /or
radiotherapy depending upon the pathological stage. Pathological
specimens sent for histopathological examination and
immunohistochemistry(IHC) for p53.
P53 nuclear overexpression in Formalin-fixed, paraffin-embedded tissue
sections has been detected by the immunohistochemical method using
monoclonal antibody. The monoclonal antibody used is Monoclonal mouse
anti-human p53 protein clone D0-7 and code No. M 7001. Monoclonal mouse
antibody supplied in liquid form as tissue culture supernatant
(RPM/1640 medium containing fetal calf serum) dialysed against 0.05 M
Tris/HCl, PH 7.2 containing 15 mM NaN3. Mouse Ig concentration is 400
mg/L, isotype is Ig G2b, Kappa and total protein concentration are
13.7g/L. Immunogen used was recombinant human wild-type p53 protein
expressed in E.coli. Monoclonal antibody recognises an epitope in the
N-terminus of the human p53 protein. The epitope for the antibody is
known to reside between amino acids 19 to 26. The antibody reacts with
wild type and mutant type of p53 protein. Overexpression is defined as
tumour with >20% of cells with positive nuclear reactivity. To
improve the staining pattern methods for antigen retrieval, such as
boiling in 10mM citrate buffer, can be used. This p53 nuclear
overexpression is correlated with tumour stage and grade. Tumour
staging according to revised TNM system AJCC-UICC 1997. Follow up done
with urine cytology and cystoscopy quarterly for 1 year, semi-annual
for 2 years and then annually for high-grade tumours (including CIS).
Inclusion
criteria– All the patients who attended urology
OPD with diagnosis of bladder cancer
Exclusion criteria–
All patients who underwent prior treatment for bladder cancer
Statistical analysis-
Statistical analysis was performed using SPSS package (version window
11.5 package). One way analysis of variance (ANOVA) was used to
estimate the differences between the study groups. Probability value P
< 0.05 was considered significant. Kaplan-Meier curve was drawn
to assess the survival rate in p53 positive and negative patients.
All-cause mortality was taken for survival.
Results
The total numbers of patients were 33 in this study. Males were 27 and
female were 6. More than 50% of patients were above 60 years of age. No
patient was seen below 30 years of age. Histopathology type was
Transitional cell carcinoma 30 (91.91%), Transitional cell carcinoma
with sarcomatoid change 1 (3.03%), Squamous cell carcinoma 1 (3.03%),
Leiomyosarcoma 1 (3.03%), and grade was low-grade tumours 8 (24.24) and
high-grade tumours 25 (75.26%). Patients were treated with
Transurethral bladder biopsy 2 (6.06%), Transurethral resection of
bladder tumour (TURBT) 31 (93.94%), Radical cystectomy with ileal
conduit 9 (27.27%), and Radical cystectomy + total urethrectomy and
continent ileal double ‘T’ pouch 1 (3.03%).
Patients with superficial bladder cancer received adjuvant intravesical
BCG instillation 13 (39.39%) and patients with nodal involvement
received adjuvant chemotherapy3 (9.09%).Primary radiotherapy given to
the patients with the poor general condition and who refuses radical
cystectomy and urinary diversion7 (21.21%).
P53 nuclear overexpression is defined as tumour with > 20% of
cells with positive nuclear reactivity. The number of patients with p53
negativity was 18 (54.55%) and the number of patients with p53
positivity was 15 (45.45%). There was a positive correlation between
the expression of mutant p53 protein and tumour stage, with only 2 of
10 PT1 tumours being positive for mutant p53 compared with 13 (56.52%)
of 23 muscle invasive and CIS (Fig:1). There was a positive
correlation between the expression of mutant p53 protein and tumour
grade, with none of 8 low-grade tumours were positive for mutant p53,
in contrast to 15 (60%) of 25 high-grade tumours. Two patients with
T1G1 tumours developed recurrence with initial TURBT and intravesical
BCG instillation after 6 months and responded to Re TURBT and
intravesical BCG instillation therapy. One patient of T1G3 developed
recurrence after 1 year with initial TURBT and intravesical BCG
instillation and responded to Re TURBT and intravesical BCG
instillation therapy. One patient of T1G3 progressed to muscle invasive
disease after 1 year and underwent Radical cystoprostatectomy with
ileal conduit. Received adjuvant chemotherapy and radiotherapy. Two
patients developed post-operative urinary leak and underwent bilateral
cutaneous ureterostomy. Mortality in p53 positive patients was 5 and
Mortality in p53 Negative patients was 4 (Table:1). 8 out of 9 patients
expired have transitional cell carcinoma and 1 had sarcomatoid
carcinoma. All patients have high-grade and muscle invasive (T2 and/ or
high stage) tumours and more than 50% were p53 positive.
Table-1: This
curve shows that survival rate of p53 positive patients is lesser than
p53 negative patients (Note: Green line is the survival rate of p53
positive, while blue line is that of p53 negative patients).
Correlations
Table-2: ANOVA
Test (one-way analysis of variance) to determine the statistical
difference of all variables between parameters
|
|
T-Stage
|
N-Stage
|
M-Stage
|
Grade
|
P53
|
Survival
|
T-Stage
|
Pearson
Correlation
|
1.000
|
0.181
|
-0.021
|
0.398*
|
0.129
|
0.140
|
Sig.
(2-tailed)
|
.
|
0.313
|
0.908
|
0.022
|
0.473
|
0.437
|
N
|
33
|
33
|
33
|
33
|
33
|
33
|
N-Stage
|
Pearson
Correlation
|
0.181
|
1.000
|
-0.087
|
0.277
|
-0.078
|
0.388*
|
Sig.
(2-tailed)
|
0.313
|
|
0.631
|
0.118
|
0.665
|
0.026
|
N
|
33
|
33
|
33
|
33
|
33
|
33
|
M-Stage
|
Pearson
Correlation
|
-0.021
|
-0.087
|
1.000
|
0.100
|
-0.161
|
0.289
|
Sig.
(2-tailed)
|
0.908
|
0.631
|
|
0.580
|
0.370
|
0.103
|
N
|
33
|
33
|
33
|
33
|
33
|
33
|
Grade
|
Pearson
Correlation
|
0.398*
|
0.277
|
0.100
|
1.000
|
0.516**
|
0.346*
|
Sig.
(2-tailed)
|
0.022
|
0.118
|
0.580
|
|
0.002
|
0.048
|
N
|
33
|
33
|
33
|
33
|
33
|
33
|
P53
|
Pearson
Correlation
|
0.129
|
-0.078
|
-0.161
|
0.516*
|
1.000
|
0.124
|
Sig.
(2-tailed)
|
0.473
|
0.665
|
0.380
|
0.002
|
|
0.491
|
N
|
33
|
33
|
33
|
33
|
33
|
33
|
Survival
|
Pearson
Correlation
|
0.140
|
0.388*
|
0.289
|
0.346*
|
0.124
|
1.000
|
Sig.
(2-tailed)
|
0.437
|
0.026
|
0.103
|
0.048
|
0.491
|
|
N
|
33
|
33
|
33
|
33
|
33
|
33
|
*correlation is significant at the 0.05 level (2-tailed).
**correlation is significant at the 0.01 level (2-tailed).
Fig-1: Carcinoma
in situ Immunohistochemistry (IHC) showing p 53 positivity
ANOVA Test (one-way analysis of variance) was done to determine the
statistical difference of all variables between parameters. The
correlation was significant between tumour grade and P53 positivity. P
value is <0.05. There was no significant correlation between P53
and tumour stage, study correlation coefficient (r) between P53 and
tumour stage was 0.129 and p-value 0.473, which was not significant
(Table:2).
Discussion
The most useful prognostic parameters in bladder cancer for tumour
recurrence and subsequent cancer progression in the patient with
superficial tumours are tumour grade, stage, lymphatic invasion, tumour
size, carcinoma in-situ in neighbouring or distant urothelial areas,
papillary or solid tumour architecture, multifocality and frequency of
tumour recurrences. The most important of these are tumour grade, stage
and presence of carcinoma in-situ. In this study P53 protein nuclear
overexpression was assessed in Formalin-fixed, paraffin-embedded tissue
sections by the immunohistochemical method using monoclonal antibody.
This p53 nuclear overexpression was correlated with tumour grade and
stage. Overall survival rate was assessed in p53 positive and negative
patients.
Abnormal expression of the receptor for EGF on malignant urothelium
correlates with increased tumor aggressiveness and is a predictor of
poor survival from disease [12,13,14] . Transforming growth factor - b
s (TGE- bs) compose a family of related proteins that include TGF - b1
to b5, mullerian inhibitory substance, inhibin and activin [15]. Tumors
with elevated expression of TGF-b (particularly TGF-b1) would have
slower proliferation and be more indolent than those with reduced
expression. This has been found using Northern blotting to detect TGF-
b1 and TGF - b2 in mRNAs by coombs and colleagues [16].
Deletions of chromosome 17 p have been associated with tumor
progression – presumably because TP 53 is lost with the
section of 17 p that is deleted. Others have looked at increased
immunohistochemical detectability of TP 53 in the nucleus as a
surrogate for genetic deletion and /or mutation [11]. Esrig and
colleagues demonstrated that increased nuclear expression of TP 53 in
formalin – fixed, paraffin-embedded sections of TCCs from
patients undergoing cystectomy correlated with reduced survival and
disease progression [17]. Several studies have failed to find
prognostic value of nuclear overexpression of TP53, independent of
tumor grade and stage, in patients with superficial bladder tumors
[2,18,19,20]. In part, this reflects variations in reagents, tissue
preparations, means of quantification, and thresholds of positivity
that various researchers have employed. The lack of technologic
consensus on these issues has significantly reduced widespread
acceptance of the prognostic utility of TP53 status.
There was a strong positive correlation between the expression of
mutant p53 and tumour grade, with none of the low grade tumours were
positive for mutant p53, in contrast to 60% of high-grade tumours.
There was there no significant correlation between p53 and tumour
stage. P value was > 0.05, which is not significant. It is
possible that because of small sample size we may not have got the
significant association between tumour stage and p53 positivity.
For superficial and invasive cancers, expressions of multiple markers,
particularly TP 53 and either RB or p21, have been investigated with
variable results [6,21]. The high frequency of loss of
heterozygosity at chromosome 17p in high grade Transitional cell
carcinoma (TCC). Genetic defects in p53 locus have been shown to
correspond with protein expression of the mutated p53 gene product. The
p53 gene encodes for a protein vital to arresting the cell cycle.
Mutations in p53 result in the production of a dysfunctional protein
product with longer half-life than the wild – type protein.
Because of this protein longevity, p53 mutated gene products accumulate
in the cell nucleus and can be easily detected by immunohistochemical
methods [22].
In this study, there was no significant difference in the mortality
between p53 positive and negative patients. P value was > 0.05,
which was not significant. Though percentages are shown significance
yet ‘P’ values did not yield significant because of
the small group of patients encountered during our study.
Conclusion
There was a positive correlation between the tumour grade and p53
nuclear overexpression. There was no significant difference in the
mortality between the p53 positive and negative tumours. Only half of
the tumours with high grade and high stage are associated with P53
nuclear overexpression. This study concludes that p53 nuclear
overexpression was not clinically useful as an independent prognostic
marker for bladder cancer. It can be used along with tumour grade and
stage.
Funding:
Nil, Conflict of
interest: None initiated.
Permission from IRB:
Yes
References
1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer
EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin. 2005
Jan-Feb;55(1):10-30. [PubMed]
2. Linn JF, Sesterhenn I, Mostofi FK, Schoenberg M. The molecular
characteristics of bladder cancer in young patients. J Urol. 1998
May;159(5):1493-6. [PubMed]
3. Crow P, Ritchie AW. National and international variation in the
registration of bladder cancer. BJU Int. 2003 Oct;92(6):563-6. [PubMed]
4. Harris CC, Hollstein M. Clinical implications of the p53
tumor-suppressor gene. N Engl J Med. 1993 Oct 28;329(18):1318-27. [PubMed]
5. Vogelstein B. Cancer. A deadly inheritance. Nature. 1990 Dec
20-27;348(6303):681-2. [PubMed]
6. Cote RJ, Chatterjee SJ. Molecular determinants of outcome in bladder
cancer. Cancer J Sci Am. 1999 Jan-Feb;5(1):2-15. [PubMed]
7. Lozano G, Elledge SJ. p53 sends nucleotides to repair DNA. Nature.
2000 Mar 2;404(6773):24-5. [PubMed]
8. Smith ML, Chen IT, Zhan Q, Bae I, Chen CY, Gilmer TM, Kastan MB,
O'Connor PM, Fornace AJ Jr. Interaction of the p53-regulated protein
Gadd45 with proliferating cell nuclear antigen. Science. 1994 Nov
25;266(5189):1376-80. [PubMed]
9. Grossfeld GD, Ginsberg DA, Stein JP, et al: Thrombospondin-1
expression in bladder cancer: Association with p53 alterations, tumour
angiogenesis, and tumour progression. J Natl Cancer
Inst 1997; 89:219-27.
10. Carr AM. Cell cycle. Piecing together the p53 puzzle. Science. 2000
Mar 10;287(5459):1765-6.
11. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ.
Activating mutations for transformation by p53 produce a gene product
that forms an hsc70-p53 complex with an altered half-life. Mol Cell
Biol. 1988 Feb;8(2):531-9.
12. Messing EM, Reznikoff CA. Normal and malignant human urothelium: in
vitro effects of epidermal growth factor. Cancer Res. 1987 May
1;47(9):2230-5. [PubMed]
13. Neal DE, Sharples L, Smith K, et al: The epidermal growth factor
receptor and the prognosis of bladder cancer.
Cancer 1990; 65:1619-25. [PubMed]
14. Popov Z, Gil-Diez-De-Medina S, Ravery V, et al: Prognostic value of
EGF receptor and tumor cell proliferation in bladder cancer:
Therapeutic implications. Urol Oncol 2004;
22:93-101.
15. Roberts AB, Sporn MB. Physiological actions and clinical
applications of transforming growth factor-beta (TGF-beta). Growth
Factors. 1993;8(1):1-9.
16. Coombs LM, Pigott DA, Eydman DA, et al: Reduced expression of
TGFβ is associated with advanced disease in transitional cell
carcinoma. Br J Cancer 1993; 67(3):578-584. [PubMed]
17. Esrig D, Elmajian D, Groshen S, Freeman JA, Stein JP, Chen SC,
Nichols PW, Skinner DG, Jones PA, Cote RJ. Accumulation of nuclear p53
and tumor progression in bladder cancer. N Engl J Med. 1994 Nov
10;331(19):1259-64. [PubMed]
18. Gardner RA, Walsh MD, Allen V, et al: Immunohistological expression
of p53 in primary pT1 transitional cell bladder cancer in relation to
tumor progression. Br J Urol 1994; 73:526-32.
19. Lebret T, Becette V, Barbagelatta M, et al: Correlation between p53
overexpression and response to bacillus Calmette-Guérin
therapy in a high risk select population of patients with pT1G3 bladder
cancer. J Urol 1998; 159:788-91.
20. Lipponen PK. Over-expression of p53 nuclear oncoprotein in
transitional-cell bladder cancer and its pro gnostic value. Int J
Cancer. 1993 Feb 1;53(3):365-70. [PubMed]
21. Cordon-Cardo C: Mutation of cell cycle
regulators—biological and clinical implications for human
neoplasia. Am J Pathol 1995; 147(3):545-60.
22. Olumni AF, Tsai YC, Nichols PW, et al: Allelic loss of chromosome
17p distinguishes high grade from low grade transitional cell
carcinomas of the bladder. Cancer Res 1990;
50:7081-3.
How to cite this article?
Reddy P. V. Prognostic value of P53 nuclear overexpression in bladder
cancer. Int J Med Res Rev 2017;5(06):569-575. doi:10.17511/ijmrr.
2017.i06.05.